Drug Type Small molecule drug |
Synonyms 希美替尼 + [1] |
Target |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists), M-CSF inhibitors(Macrophage Colony Stimulating Factor 1 inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Esophageal Squamous Cell Carcinoma | Phase 3 | - | 31 Oct 2024 | |
Esophageal Squamous Cell Carcinoma | Phase 3 | CN | 13 Sep 2024 | |
HER2-Low Breast Carcinoma | Phase 2 | CN | 22 Aug 2024 | |
HR-positive/HER2-low Solid Tumors | Phase 2 | CN | 30 Jan 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 07 Dec 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 07 Dec 2023 | |
Bile Duct Neoplasms | Phase 2 | CN | - | |
Endometrial Carcinoma | Phase 2 | CN | - | |
squamous cell lung carcinoma | Phase 2 | CN | - | |
Stomach Cancer | Phase 2 | CN | - |
NCT04058587 (ASCO2024) Manual | Phase 1 | Advanced Malignant Solid Neoplasm FGF3 | FGF4 | FGF19 | 98 | Simmitinib 4 mg QD | (ybzoqbnhxj) = MTD was not achieved uexkqdfxzd (yvpusuglwq ) View more | Positive | 24 May 2024 |
Simmitinib 6 mg QD |